CAR-T疗法在治疗肿瘤免疫逃逸中的研究进展

The research progress of CAR-T therapy in the treatment of tumor immune escape

机体内的免疫系统可以对肿瘤细胞产生免疫应答从而进一步消除肿瘤。但部分肿瘤能在宿主体内生长、转移和突变,表明其具有免疫逃逸的能力。肿瘤细胞抗原本身发生逃逸、效应细胞功能强弱、肿瘤细胞微环境等都与肿瘤的免疫逃逸密切相关。近年来,以嵌合抗原受体T(CAR-T)细胞疗法为主的免疫疗法在肿瘤的治疗领域发展迅猛,正逐渐成为治疗肿瘤的主流方向,本文对治疗肿瘤免疫逃逸中CAR-T的应对治疗策略和进展进行梳理,旨在为CAR-T疗法治疗肿瘤的下一步发展优化思路。

The body's immune system can produce an immune response to tumor cells to further eliminate tumors.However,some tumors can grow,metastasize and mutate in the host,indicating that they have the ability to escape immune.The escape of tumor cell antigens,the function of effector cells,and the microenvironment of tumor cells are all closely related to the immune escape of tumors.In recent years,immunotherapy based on chimeric antigen receptor T cell therapy(CAR-T therapy)has developed rapidly in the field of tumor treatment,and is gradually becoming the mainstream direction of tumor treatment.This article is about CAR-T in the treatment of tumor immune escape.To sort out the treatment strategies and progress of CAR-T therapy,aiming to clarify the ideas for the next development and optimization of CAR-T therapy for tumors.